Inhibition of protein-protein association by small molecules: Approaches and progress

Journal of Medicinal Chemistry

Volumn 45, Issue 8, 2002, Pages 1543-1558

  Toogood, Peter L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; ANALGESIC AGENT; ANTIMITOTIC AGENT; ANTIMYCIN A1; AP 22161; AP 22408; APOPTOSIS INDUCING FACTOR; CHEMOKINE RECEPTOR; DANSYLCADAVERINE; DNA FRAGMENT; E 8; ENZYME INHIBITOR; ETHANOLAMINE DERIVATIVE; GELATINASE A; GELATINASE INHIBITOR; GELDANAMYCIN; HERBIMYCIN A; INDOLE DERIVATIVE; IODINE 125; N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE; N (6 AMINOHEXYL) 1 NAPHTHALENESULFONAMIDE; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N [5 NITRO 1H BENZ[DE]ISOQUINOLINE 1,3(2H) DIONE] 2 AMINOETHANOL; NERVE GROWTH FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PACLITAXEL; PROTEIN; PROTEIN BCL 2; PROTEIN P75; PU 3; RANTES; TACROLIMUS; TRIFLUOPERAZINE; TSR 1265; UCS 15A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BINDING COMPETITION; CANCER; CLINICAL TRIAL; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; IMMUNOPRECIPITATION; MITOSIS; NONHUMAN; PHENOTYPE; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANIMALS; BINDING, COMPETITIVE; DRUG DESIGN; LIGANDS; MOLECULAR MIMICRY; PEPTIDES; PROTEIN BINDING;

EID: 0037061646     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010468s     Document Type: Review

References (92)

1. Protein-protein interactions: Interface structure, binding thermodynamics, and mutational analysis
2. Principles of protein-protein interactions
3. Binding in the growth hormone receptor complex
4. A novel single-molecule study to determine protein-protein association constants
5. Antagonists of protein-protein interactions
6. Inhibition of the assembly of protein-protein interfaces
7. Recent advances in αvβ3 integrin inhibitors
8. GPIIb/IIIa antagonists
9. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat
10. A small-molecule nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
11. The chemokine/chemokine-receptor family: Potential and progress for therapeutic intervention
12. Chemokine receptor antagonists
13. Chemokines: Targets for novel therapeutics
14. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin αvβ3
15. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo
16. Trifluoroperazine, a calmodulin antagonist, inhibits muscle cell fusion
17. Inhibition by trifluoroperazine of calmodulin-induced activation of ATPase activity of rat erythrocyte
18. Small-molecule inhibitors of HIV-1 protease dimerization from cross-linked interfacial peptides
19. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry
20. Time-resolved fluorometry: An overview of the labels and core technologies for drug screening applications
21. High-throughput screening: New technology for the 21st century
22. Bcl-2 family proteins as targets for anticancer drug design
23. Mechanisms of apoptosis
24. Apoptosis signaling
25. L
26. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α
27. Antimycin A mimics a cell-death-inducing bcl-2 homology domain 3
28. Structure-based discovery of an organic compound that binds bcl-2 protein and induces apoptosis of tumor cells
29. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein
30. Dissecting cellular processes using small molecules: Identification of colchicine-like, taxol-like and other small molecules that perturb apoptosis
31. UCS15A, a non-kinase inhibitor of Src signal transduction
32. A novel genetic system to detect protein-protein interactions
33. Controlling protein association and subcellular localization with a synthetic ligand that induces dimerization of proteins
34. A three-hybrid system for detecting small ligand-protein receptor interactions
35. A novel indication of the activities of small molecule inhibitors of protein-protein interactions: Application of the yeast two-hybrid system
36. A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets
37. Src homology-2 domains: Structure, mechanisms, and drug discovery
38. Nonpeptidic, monocharged, cell permeable ligands for the p56lck SH2 domain
39. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways
40. Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain
41. 2
42. Structure-based design, synthesis, and x-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic
43. Highly potent inhibitors of the Grb2-SH2 domain
44. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic
45. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands
46. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions
47. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a
48. A new small molecule C5a receptor antagonist inhibits the reverse-passive arthus reaction and endotoxic shock in rats
49. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53
50. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
51. On the interaction between p53 and MDM2: Transfer NOE study of a p53-derived peptide ligated to MDM2
52. Nonpeptidal peptidomimetics with β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist
53. CAVEAT: A program to facilitate the design of organic molecules
54. Design and synthesis of small molecule interleukin-1 receptor antagonists based on a benzene template
55. A novel vascular relaxing agent. N-(6-aminohexyl)-5-chloro-1-naphthylsulfonamide, which affects vascular smooth muscle actomyosin
56. Symmetric covalent linkage of N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) results in novel derivatives with increased inhibitory activities against calcium/calmodulin complex
57. Designed molecules that fold to mimic protein secondary structures
58. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix
59. Hsp90 & Co. a holding for folding
60. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
61. The Hsp90 complex - A super-chaperone machine as a novel drug target
62. Hsp90: A specialized but essential protein-folding tool
63. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone
64. Crystal structure of an Hsp90-geldanamycin complex: Targetting of a protein chaperone by an antitumor agent
65. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells
66. src SH2 domain
67. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
68. Structure-based design of an osteoclast-selective nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity
69. The formation of a covalent complex between a dipeptide ligand and the Src SH2 domain
70. Allosteric drugs: Thinking outside the active-site box
71. Pharmacological rescue of mutant p53 conformation and function
72. Antimitotic natural products and their interaction with tubulin
73. How taxol stabilizes microtubule structure
74. Structural basis for the action of drugs that affect microtubule dynamics
75. Designing small-molecule switches for protein-protein interactions
76. Controlling signal transduction with synthetic ligands
77. Dexamethasone-methotrexate: An efficient chemical inducer of protein dimerization in vivo
78. Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces
79. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
80. Synthesis and evaluation of geldanamycin-testosterone hybrids
81. Synthesis and evaluation of geldanamycin-estradiol hybrids
82. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
83. A ligand-reversible dimerization system for controlling protein-protein interactions
84. Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum
85. Analysis of the binding surfaces of proteins
86. Rapid mapping of protein functional epitopes by combinatorial alanine scanning
87. Computational alanine scanning to probe protein-protein interactions: A novel approach to evaluate binding free energies
88. Exploring the specificity pockets of two homologous SH3 domains using structure-based, split-pool synthesis and affinity-based selection
89. Discovering high affinity ligands for proteins: SAR by NMR
90. On the attribution additivity of binding energies
91. Covalent modification as a strategy to block protein-protein interactions with small molecule drugs